MOESM2 of Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36Â monthsA Riccio, Giorgio Walter Canonica, Laura De Ferrari et al.|Figshare|2017Cited by 0